MTOR and ependymoma: For example, a study from Rogers et al. identified P-AKT protein expression, indicating PI3K-mTOR pathway activation, was present in 72% of 169 pediatric ependymomas tumors.32 P-AKT expression was found to be an independent marker of a poorer progression-free survival, suggesting that PI3K-mTOR pathway activation could be both a prognostic biomarker and potential therapeutic target for pediatric ependymomas.